Colorado Clinical Trials Report — May 2026

For Coloradans considering participation in clinical research, May 2026 presents a crucial window of opportunity, particularly for those looking to join studies that are nearing their enrollment deadlines. Across the state, 125 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 21 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various types of cancer, neurological disorders, and mental health are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer
• Advanced solid tumor
• Cancer (general)
• Smoking cessation
• Mental health
• Parkinson disease
• B-cell acute lymphoblastic leukemia
• Endothelial dysfunction

Major Research Initiatives Launch in Colorado

This month brings several high-profile new trials to Colorado, including significant Phase 3 studies from major pharmaceutical companies and leading academic institutions. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic tools, addressing a range of health challenges from metabolic disorders to aging and cardiovascular health.

• Novo Nordisk A/S is sponsoring NCT07567001, a Phase 3 study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This substantial trial aims to enroll 5,610 participants globally, evaluating the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight.
• Another significant Phase 3 study from Novo Nordisk A/S is NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This trial seeks to enroll 2,500 participants to assess the safety and effectiveness of CagriSema for body weight loss in people with obesity, with or without type 2 diabetes.
• Longevity Metrics, Inc. is leading NCT07563777, an observational study named "100-Year Human Aging Study." This ambitious trial plans to enroll 10,000 participants to undergo comprehensive multi-system health screening and longitudinal follow-up until death, aiming to determine whether measurements taken over time can predict health outcomes related to aging.
• The University of Colorado, Denver is sponsoring NCT07569224, a study titled "Testing the Impact of the MOHR Follow-up Support." This research will involve 1,000 participants and evaluate the impact of three different strategies to increase engagement in My Own Health Report (MOHR) and health behavior change activities over time, assessing engagement levels, outcomes, cost, and cost-effectiveness.

Colorado's Evolving Research Landscape

This month, Colorado saw the opening of only 7 new clinical trials, a notable decrease compared to the 21 trials that launched in April 2026. Despite this dip in new openings, the state continues to offer a broad array of research opportunities, with a total of 1,775 clinical trials currently recruiting across 56 cities and 1,013 research sites.

The majority of new research initiatives this month are concentrated in the Denver metropolitan area. Aurora leads with 4 new trials, followed by Denver with 2, and Westminster with 2. Other cities like Lone Tree, Englewood, Boulder, and Golden each saw 1 new trial open. This indicates a continued clustering of new research opportunities around the state's larger urban centers, enhancing accessibility for residents in these areas.

New studies are exploring a range of conditions, from common ailments to more specialized areas. This month's new trials are targeting:

• Obesity
• Aging
• Aging well
• All-cause mortality
• Cardiovascular diseases
• Cognitive-behavioral therapy
• Cognitive dysfunction
• Dementia
• Depression in adolescence
• Physical disability

The types of interventions being studied are varied, with behavioral and device trials each accounting for 2 of the new trials, alongside 2 drug trials, 1 diagnostic test, and 1 other type of research.

Diverse Participation: Healthy Volunteers and Specific Demographics

Participation in clinical trials is open to a wide range of individuals. Of the 7 new trials launched this month, 5 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials are open to children, offering opportunities for younger participants to engage in research that could benefit their age group.

For individuals without a specific medical condition, there are significant opportunities to contribute. 2 of the new trials this month are actively seeking healthy volunteers. Across Colorado, a total of 206 trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Academic institutions continue to play a vital role in Colorado's research ecosystem, with the University of Colorado, Denver sponsoring 2 of the new trials, and Colorado State University sponsoring 1. Industry sponsors, including Novo Nordisk A/S, are also driving significant research efforts, accounting for 2 of the new studies this month. Longevity Metrics, Inc. and Pulse Wave USA are also notable sponsors contributing to the state's research landscape.

As we move through May, the focus will likely shift towards the ongoing enrollment in these significant Phase 3 trials and the large-scale aging study, while researchers prepare for the next wave of innovative studies to address a broad spectrum of health challenges across Colorado.